XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 54.59

Change

+0.23 (+0.42)%

Market Cap

USD 0.85B

Volume

232.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.13 (-0.47%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.29 (-0.54%)

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

-3.84 (-0.63%)

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.31 (-0.53%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.08 (-0.51%)

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.20 (+0.08%)

USD 52.42B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.70 (-0.63%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.37 (+0.34%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 38.52B
0ZC:F Zscaler Inc

-2.56 (-1.40%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.58% 71% C- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.58% 70% C- 56% F
Trailing 12 Months  
Capital Gain 6.33% 42% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.33% 39% F 46% F
Trailing 5 Years  
Capital Gain 46.63% 75% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.63% 74% C 54% F
Average Annual (5 Year Horizon)  
Capital Gain 11.05% 72% C 67% D+
Dividend Return 11.05% 70% C- 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.68% 64% D 89% A-
Risk Adjusted Return 103.45% 94% A 95% A
Market Capitalization 0.85B 73% C 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike